|
ISPOR 8th Annual European Congress
6-8
November 2005, Palazzo Degli Affari, Florence, Italy
|
|
POSTER PRESENTATIONS - SESSION II |
|
Monday, 7 November
2005, 8:00-20:00 |
CARDIOVASCULAR DISEASE
|
PCV1 |
|
COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN
PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN
HUNGARY
Borsos K1, Nagy B2, Spiesser J3,
Gabriel S3, Blaskó G1
1sanofi-aventis, Budapest, Hungary; 2 University of
Debrecen, Debrecen, Hungary; 3 Sanofi-Aventis, Bagneux, France |
|
|
PCV2 |
|
COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80
MG ATORVASTATIN VS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME: AN
ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN OR ATORVASTATIN
EVALUATION AND INFECTION THERAPY).
F Bobadilla J1, García M2
1Pfizer SA, Alcobendas/Madrid, Spain; 2 Euroclin
Institute, Madrid, Spain |
|
|
PCV3 |
|
A PHARMACO-ECONOMIC EVALUATION OF AGGRESSIVE
CHOLESTEROL LOWERING AFTER ACUTE CORONARY SYNDROME IN BELGIUM: A
SHORT-TERM AND LONG-TERM ASSESSMENT
Annemans L1,
Van Campenhout H2, Matthys K2, Casciano RN3,
Budts W4
1IMS Health, Brussels, Belgium; 2 Pfizer, Brussels,
Belgium; 3 Analytica International, Loerrach, Germany; 4
UZ Gasthuisberg, Leuven, Belgium |
|
|
PCV4 |
|
HOW MUCH IS THE ACUTE CORONARY SYNDROMES IN-HOSPITAL
THERAPY: A PILOT STUDY ON THERAPY
Adameová A1, Foltán V1, Kasper J2,
Michalíková A3, Borecký P3
1Comenius University-Faculty of Pharmacy, Bratislava, Slovak
Republic; 2 Comenius University-Faculty of Medicine,
Bratislava, Slovak Republic; 3 Sanofi-Aventis, Bratislava,
Slovak Republic |
|
|
PCV5 |
|
COST-EFFECTIVENESS OF DRUG ELUTING STENTS FOR STABLE
ANGINA
Kristiansen IS
University of Oslo, Oslo, Norway |
|
|
PCV6 |
|
IMPACT OF STATIN THERAPY INTENSITY ON ALL-CAUSE
MORTALITY FOLLOWING CARDIOVASCULAR HOSPITALIZATION IN A MANAGED CARE
POPULATION
Fintel DJ1, Joyce A2,
Mackell JA3, Graff J3, Kuntze CE3
1Northwestern University, Chicago, IL, USA; 2
PharMetrics, Inc, Stamford, CT, USA; 3 Pfizer, Inc, New York,
NY, USA |
|
|
PCV7 |
|
COSTS OF DIAGNOSIS OF ARRHYTHMOGENIC RIGTH
VENTRICULAR CARDIOMYOPATHY IN INDIVIDUALS WITH A FAMILY HISTORY OF THE
DISEASE IN POLAND
Glinka M, Kowalik E, Wlodarska EK, Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland |
|
|
PCV8 |
|
COST OF HOSPITALIZATION FOR PATIENTS WITH
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY IN POLAND
Kowalik E, Glinka M, Wlodarska EK, Wozniak O, Hoffman P
Institute of Cardiology, Warsaw, Poland |
|
|
PCV9 |
|
THE EFFECT OF ANTICOAGULATION FOR STROKE PREVENTION
IN PATIENTS WITH ATRIAL FIBRILLATION – COMPARING EFFICACY AND
EFFECTIVENESS
Dewilde S1, Sorensen SV2, Brown R3,
Monz B4
1The MEDTAP Institute at UBC, Brussels, Belgium; 2
The MEDTAP Institute at UBC, Bethesda, MD, USA; 3 MedTap
Institute at UBC, London, United Kingdom; 4 Boehringer
Ingelheim, Ingelheim, Germany |
|
|
PCV10 |
|
DRIVERS OF UNDERUSE OF VITAMIN K ANTAGONISTS IN
PATIENTS WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION IN FRANCE: THE
ENSEFAL STUDY
Guenoun M1, Le Jeunne P2,
Lamarque H3
1Clinique Bouchard, Marseille, France; 2
BKL-Thales, Boulogne Billancourt, France; 3 AstraZeneca
France, Rueil-Malmaison, France |
|
|
PCV11 |
|
ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR ATRIAL
FIBRILLATION: AN EVALUATION OF STABILITY AND EARLY FACTORS THAT PREDICT
LONGER-TERM STABILITY ON WARFARIN IN A LARGE UK POPULATION
Currie CJ1, McEwan P2, Emmas C3,
Peters JR4
1Cardiff University, Cardiff, United Kingdom; 2
Cardiff University, Cardiff, Wales, United Kingdom; 3
AstraZeneca-UK, Luton, Bedfordshire, United Kingdom; 4
University Hospital of Wales, Cardiff, United Kingdom |
|
|
PCV12 |
|
MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION
IN A LARGE COMMERCIALLY INSURED U.S. POPULATION
Fidan D1, Ollendorf D2, Leguet P1,
Gabriel S1, Boccuzzi S2
1Sanofi-Aventis, Bagneux Cedex, France; 2
PharMetrics, Inc, Watertown, MA, USA |
|
|
PCV13 |
|
EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS
Diotallevi P1, Occhetta E2, Martinelli V3,
Zaccone G4,
Ponzi P5, Scivales A5, Caprari F5
1Ospedale SS. Antonio e Biagio e Cesare Arrigi, Alessandria,
Italy; 2 Ospedale Maggiore della Caritŕ, Novara, Italy; 3
Ospedale SS.Antonio e Margherita, Tortona (AL), Italy; 4
Ospedale S. Giacomo, Novi Ligure (AL), Italy; 5 Fondazione
Medtronic Italia, Sesto San Giovanni (MI), Italy |
|
|
PCV14 |
|
THE COST OF ANTICOAGULATION MONITORING SERVICES IN
THE UK NATIONAL HEALTH SERVICE
Arya R1, Green ES2, Rose P3, Dolan G4,
Wimperis JZ5, Tait RC6, Plumb J7,
Emmas C7
1Kings College Hospital, London, United Kingdom; 2
Swindon and Marlborough NHS Trust, Swindon, Wiltshire, United Kingdom;
3 University Hospitals of Coventry and Warwickshire NHS Trust,
Warwick, Warwickshire, United Kingdom; 4 University of
Nottingham, Nottingham, Notts, United Kingdom; 5 Norfolk and
Norwich University Hospital, Norwich, Norfolk, United Kingdom; 6
Royal Infirmary, Glasgow, Scotland, United Kingdom; 7
AstraZeneca UK, Luton, Bedfordshire, United Kingdom |
|
|
PCV15 |
|
SURVEY OF CURRENT ANTICOAGULANT MONITORING SERVICES
IN THE UK – A GENERAL PRACTICE PERSPECTIVE
Emmas C, Plumb J
AstraZeneca UK, Luton, Bedfordshire, United Kingdom |
|
|
PCV16 |
|
KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE
PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN
GERMANY
Burkowitz J1, Brüggenjürgen B2
1Alpha Care GmbH, Celle, Germany; 2 Charité -
Universitätsmedizin Berlin, Institut für Sozialmedizin, Epidemiologie und
Gesundheitsökonomie, Berlin, Germany |
|
|
PCV17 |
|
VKA TREATMENT RELATED COSTS IN FRANCE IN PATIENTS
WITH CHRONIC NONVALVULAR ATRIAL FIBRILLATION : COST DATA FROM THE
INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)
Drouet L1, Duru G2, Mahe I1, Bergmann JF1,
Bal dit Sollier C1, Hollowel J3, Gauchoux R4,
Woessner M5,
Lamarque H5
1Hôpital Lariboisičre, Paris, France; 2 Universite
Claude Bernard Lyon I, Lyon, France; 3 AstraZeneca R&D
Mölndal, Mölndal, Sweden; 4 Naxis, Lyon, France; 5
Laboratoires AstraZeneca, Paris, France |
|
|
PCV18 |
|
WHEN SHOULD PATIENTS BE SWITCHED FROM VKA TO NEW
TREATMENT: DEVELOPMENT AND PILOT TESTING OF A SELF-REPORTED QUESTIONNAIRE
TO TARGET PATIENTS WHO WOULD BENEFIT MOST
Arnould B1, Benmedjahed K2, Alessi MC3,
Cohen A4, Guenoun M5, Mismetti P6,
Compagnon A7
1Mapi Values, Lyon, Rhone, France; 2 Mapi Values,
Lyon, France; 3 La Timone Hospital, Marseille, France; 4
Saint Antoine Hospital, Paris, France; 5 Centre médical des
spécialistes, Plan de Cuques, France; 6 Bellevue Hospital,
Saint Etienne, France; 7 Astra Zeneca, Rueil Malmaison, France |
|
|
PCV19 |
|
A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES
(PRO) USED IN ATRIAL FIBRILLATION
Staniek V1, Minjoulat-Rey MC2, Gabriel S2,
Emery MP1, Arnould B3, Prost L3, Bouin O4
1Mapi Research Trust, Lyon, Rhone, France; 2
SANOFI-AVENTIS, Bagneux Cedex, Ile-De-France, France; 3 Mapi
Values, Lyon, Rhone, France; 4 SANOFI-AVENTIS, Bagneux,
Ile-De-France, France |
|
|
PCV20 |
|
PHARMACOTHERAPY AND OUTCOMES AMONG VETERANS WITH
CHRONIC HEART FAILURE (2000-2002)
Johnson ML, Henderson L, Hasche J, Yu HJ, Petersen N, Espadas D,
Moffett M, Deswal A
Baylor College of Medicine, Houston, TX, USA |
|
|
PCV21 |
|
COST EFFECTIVENESS ANALYSIS OF BISOPROLOL TREATMENT
FOR HEART FAILURE
Menditto E1, De Portu S2, Cammarota S3,
Scalone L4, Mantovani L2
1university of naples, naples, naples, Italy; 2
University of Naples, Naples, Italy; 3 University of Naples,
Naples, Naples, Italy; 4 Center of Pharmacoeconomics, Milan,
Italy |
|
|
PCV22 |
|
CASE-BASED-COSTING VS. MARKOV-MODELLING – A
COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS
WITH CHRONIC HEART FAILURE
Voelkl M,
Pirk O, Juenger V
Fricke & Pirk GmbH, Nuremberg, Germany |
|
|
PCV23 |
|
ECONOMIC EVALUATION OF VALSARTAN IN PATIENTS WITH
CHRONIC HEART FAILURE IN THE HUNGARIAN HEALTH CARE SETTING
Kósa J1, Reed SD2, Radeva J2
1Novartis Hungary, Budapest, Pest, Hungary; 2 Duke
Clinical Research Institute, Durham, North Carolina, USA |
|
|
PCV24 |
|
COST-EFFECTIVENESS ANALYSIS OF ALDOSTERONE BLOCKADE
WITH EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL
INFARCTION (EPHESUS) IN THE FRENCH CONTEXT
De Pouvourville GA1, Beillat M2
1INSERM, Le Kremlin Bicętre, France; 2 Pfizer,
Paris, France |
|
|
PCV25 |
|
THE ADD-ON TREATMENT WITH METOPROLOL SUCCINATE IN
PATIENTS WITH CHRONIC HEART FAILURE (CHF) LEADS TO COST SAVINGS IN THE
GERMAN HEALTH CARE SYSTEM – A MODEL APPROACH
Hass B,
Fricke FU, Kotowa W
Fricke & Pirk GmbH, Nuremberg, Germany |
|
|
PCV26 |
|
COST-EFFECTIVENESS OF CANDESARTAN IN GERMANY FOR
PATIENTS WITH CHRONIC HEART FAILURE
Voelkl M,
Pirk O, Juenger V
Fricke & Pirk GmbH, Nuremberg, Germany |
|
|
PCV27 |
|
COSTS AND OUTCOMES AFTER FIRST HEART FAILURE
HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES
Morsanutto A1, Mantovani L2, Ros B3,
De Portu S2, Spazzapan D3, Tosolini F3
1University of Milan, Milan, Italy; 2 University of
Naples, Naples, Italy; 3 Direzione Regionale della Sanitŕ e
delle Politiche Sociali, Regione Friuli Venezia Giulia, Trieste, Italy |
|
|
PCV28 |
|
IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT
ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN
CONVERTING ENZYME INHIBITORS (ACEIS)
Alabbadi I1, McElnay J1, Crealey G1,
Scott M2, Mairs J2
1Queen's University Belfast, Belfast, United Kingdom; 2
United Hospitals Trust, Belfast, United Kingdom |
|
|
PCV29 |
|
USE OF CONTRAST ECHOCARDIOGRAPHY: A REVIEW OF
CLINICAL DATA USING A SYSTEMATIC APPROACH
Cottrell S1, Richardson R1, Lewis S1,
Yankah E1, Chambers M2
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, United Kingdom; 2 GE Healthcare, Amersham,
United Kingdom |
|
|
PCV30 |
|
CLOPIDOGREL LOADING DOSE AND CARDIOVASCULAR OUTCOMES
IN ACUTE CORONARY SYNDROME PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY
INTERVENTION
Wang C1, He J1,
Bae JP2, McCollam PL2, Griffin BT1
1Solucient, Inc, Berkeley Heights, NJ, USA; 2 Eli
Lilly and Company, Indianapolis, IN, USA |
|
|
PCV31 |
|
COST-EFFECTIVENESS OF CONTRAST ECHOCARDIOGRAPHY IN
THE DIAGNOSIS OF CORONARY ARTERY DISEASE
Richardson R1, Cottrell S1, Aristides M1,
Chambers M2
1M-TAG, A division of IMS Health Economics and Outcomes
Research, London, United Kingdom; 2 GE Healthcare, Amersham,
United Kingdom |
|
|
PCV32 |
|
LONG-TERM COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE
CORONARY SYNDROMES BASED ON CURE AND PCI-CURE IN POLAND
Pietrasik AL1, Niewada M2, Budaj A3,
Kochman J1, Horszczaruk G1, Gabriel S4,
Spiesser J5, Yuan Y6
1Medical University of Warsaw, Warsaw, Warsaw, Poland; 2
Medical University of Warsaw, Warsaw, Poland; 3 Postgraduate
Medical School, Grochowski Hospital, Warsaw, Poland; 4
sanofi-aventis, Bagneux, France; 5 Sanofi-Synthelabo
Recherche, Bagneux, France; 6 Bristol-Myers Squibb Company,
Plainsboro, NJ, USA |
|
|
PCV33 |
|
A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN
THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN
COUNTRIES
Lamotte M1, Annemans L1, Evers T2,
Kubin M2
1IMS Health, Brussels, Belgium; 2 Bayer Healthcare
AG, Wuppertal, Germany |
|
|
PCV34 |
|
WITHDRAWN |
|
|
PCV35 |
|
HOSPITALIZATIONS FOR CARDIOVASCULAR EVENTS: FRENCH
DRG ANALYSIS
Erard C1,
Lamarsalle L2, Cotte C2, Beillat M3,
Solesse de Gendre A3
1Clinique Bouchard, Marseille, France; 2 IMS Health
- GYD Institut, LYON, France; 3 Pfizer, Paris, France |
|
|
PCV36 |
|
USE OF ABCIXIMAB IN PATIENTS UNDERGOING PERCUTANEOUS
CORONARY INTERVENTION (PCI) IN FRANCE
Fillon F1, Macé J2, Chemali N1,
De Kervasdoué J2
1Lilly, Suresnes Cedex, France; 2 Conservatoire
National des Arts et Métiers, Paris, France |
|
|
PCV37 |
|
USE OF TIME-STAMPED HOSPITAL DATA TO EXAMINE CARE
PATTERNS OF ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS
CORONARY INTERVENTION
Wang C1, He J1, McCollam PL2,
Bae JP2, Griffin BT1
1Solucient, Inc, Berkeley Heights, NJ, USA; 2 Eli
Lilly and Company, Indianapolis, IN, USA |
|
|
PCV38 |
|
THIENOPYRIDINE THERAPY IN ACUTE CORONARY SYNDROME
PATIENTS RESIDING IN GERMANY
Lage M1, McCollam PL2,
Bae JP2
1HealthMetrics Outcomes Research, LLC, Groton, CT, USA; 2
Eli Lilly and Company, Indianapolis, IN, USA |
|
|
PCV39 |
|
THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY OF
LIFE AFTER CORONARY STENT IMPLANTATION
Brüggenjürgen B1, Mcbride D2, Willich S1
1Charité - Universitätsmedizin Berlin, Institut für
Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Berlin, Germany;
2 Universitätsmedizin Berlin, Charité, Berlin, Germany |
|
|
PCV40 |
|
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH
CORONARY HEART DISEASE: A STUDY USING EQ-5D QUESTIONNAIRE
De Portu S1, Monzini M2, Galietti M3,
Mantovani LG2
1University of Naples, Naples, Italy; 2 Center of
Pharmacoeconomics, Milan, Italy; 3 University of Milan, Milan,
Italy |
|
|
PCV41 |
|
PORTUGUESE ACTIVE POPULATION HEALTH RELATED QUALITY
OF LIFE RESULTS USING THE SF-6D
Ferreira LN1, Ferreira PL2
1University of Algarve, Faro, Algarve, Portugal; 2
University of Coimbra, Coimbra, Coimbra, Portugal |
|
|
PCV42 |
|
RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA
AND GOAL ATTAINMENT
Goettsch WG
PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands |
|
|
PCV43 |
|
IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES ON
TREATMENT OF HYPERCHOLESTEROLEMIA IN DAILY PRACTICE
Goettsch WG
PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands |
|
|
PCV44 |
|
COST-EFFECTIVENESS OF ROSUVASTATIN IN THE PREVENTION
OF ISCHEMIC HEART DISEASE IN PORTUGAL
Gouveia-Pinto C1, Carrageta M2,
Silva-Miguel L3
1Instituto Superior de Economia e Gestăo, Technical University
of Lisbon, Lisbon, Portugal; 2 Garcia de Orta Hospital,
Almada, Portugal; 3 Research Centre on the Portuguese Economy
– CISEP, Lisbon, Portugal |
|
|
PCV45 |
|
THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL
INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND
Sintonen H1, Alemao E2, Jousilahti P1,
Davies G3, Kujala V4, Yin D2, Cook J3
1University of Helsinki, Mannerheimintie, Helsinki, Finland;
2 Merck and Co, Whitehouse Station, NJ, USA; 3
Merck and Co, Blue Bell, PA, USA; 4 MSD Finland, Keilaranta,
Espoo, Finland |
|
|
PCV46 |
|
COST- ANALYSIS OF HYPERCHOLESTEROLEMIA TREATMENTS
WITHIN THE SLOVAK PHARMACEUTICAL MARKET
Tesar T1, Foltan V1, Tomek D2,
Visnansky M1
1Faculty of Pharmacy, Comenius University, Bratislava, Slovak
Republic; 2 Health Insurance fund Apollo, Bratislava, Slovak
Republic |
|
|
PCV47 |
|
ROSUVASTATIN 40 MG VERSUS ATORVASTATIN 80 MG IN
HIGH-RISK PATIENTS WITH HYPERCHOLESTEROLAEMIA: ECONOMIC ANALYSIS OF THE
POLARIS STUDY
Miller PS1, Leiter LA2, Davies A3,
Sosef F4
1AstraZeneca UK, Macclesfield, Cheshire, United Kingdom;
2 University of Toronto, Toronto, Ontario, Canada; 3
Medtap International, London, United Kingdom; 4 Astrazeneca
Uk, Macclesfield, Cheshire, United Kingdom |
|
|
PCV48 |
|
ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL
ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY
(EZETIMIBE/SIMVASTATIN) IN SPAIN
Davies G1, Nocea G2, Alemao E3,
Yin D3, Cook J1
1Merck and Co, Blue Bell, PA, USA; 2 Merck, Sharp &
Dohme, Madrid, Spain; 3 Merck and Co, Whitehouse Station, NJ,
USA |
|
|
PCV49 |
|
BELGIAN EVALUATION OF SCREENING AND TREATMENT OF
HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)
De Backer G1, Brohet C2, Sheen AJ3,
Van Gaal L4, Vandenhoven G5, Vissers E5,
Schockaert B5
1Ghent University, Ghent, BC, Belgium; 2 University
of st-Luc, Brussels, Belgium; 3 University of Liege, Liege,
Belgium; 4 University Hospital Antwerpen, Antwerpen, Belgium;
5 Astrazeneca, Brussels, Belgium |
|
|
PCV50 |
|
A MULTILEVEL ANALYSIS ON PRESCRIBED STATINES IN A
BOLOGNA HEALTH AUTHORITY FROM 2000 TO 2003
Roli G1, Cavrini G1, Pandolfi P2
1University of Bologna, Bologna, Italy, Italy; 2
Health Authority of Bologna, Bologna, Italy, Italy |
|
|
PCV51 |
|
PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY
SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN
10/20 MG) IN SPAIN
Nocea G1, Davies G2, Caloto MT1,
Alemao E3, Yin D3, Cook J2
1Merck, Sharp & Dohme, Madrid, Spain; 2 Merck and
Co, Blue Bell, PA, USA; 3 Merck and Co, Whitehouse Station,
NJ, USA |
|
|
PCV52 |
|
IMPACT OF COMPLIANCE AND PERSISTENCE OF TREATMENT
WITH VALSARTAN ON HYPERTENSION CLINICAL OUTCOMES
Halpern MT1, Khan Z2, Daley W3,
Stewart WF4, Vincze G2
1Exponent, Alexandria, VA, USA; 2 Novartis Pharma
AG, Basel, Switzerland; 3 Novartis Pharmaceuticals Corp, East
Hanover, NJ, USA; 4 Geisinger Health System, Danville, PA, USA |
|
|
PCV53 |
|
PATIENT PROFILE AND STATINS EFFECTIVENESS IN USUAL
CARE
Sicras Mainar A1,
F Bobadilla J2, Rosales MJ3
1Badalona Servicios Asistenciales, Badalona, Spain; 2
Pfizer SA, Alcobendas/Madrid, Spain; 3 Pfizer SA, Alcobendas,
Madrid, Spain |
|
|
PCV54 |
|
CARDIOVASCULAR RISK CONTROL IN HYPERTENSION AND/OR
DYSLIPIDEMIA IN PRIMARY CARE
Sicras Mainar A1,
F Bobadilla J2, Aristegui R3
1Badalona Servicios Asistenciales, Badalona, Spain; 2
Pfizer SA, Alcobendas/Madrid, Spain; 3 Pfizer SA, Alcobendas
(Madrid), Spain |
|
|
PCV55 |
|
EVALUATION OF COSTS RELATED TO HYPERTENSION IN
PATIENTS WITH UNCONTROLLED HYPERTENSION IN POLAND
Hermanowski T1, Jaworski R2, Czech M2,
Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2
Servier Poland, Warsaw, Poland |
|
|
PCV56 |
|
EVALUATION OF COSTS RELATED TO HYPERTENSION IN
PATIENTS WITH CONCOMITANT DISEASES IN POLAND
Hermanowski T1,
Jaworski R2, Czech M2, Pachocki R2
1Warsaw University of Technology, Warsaw, Poland; 2
Servier Poland, Warsaw, Poland |
|
|
PCV57 |
|
COST-EFFECTIVENESS OF NEBIVOLOL VERSUS ATENOLOL AND
ACE INHIBITOR MONOTHERAPY IN PATIENTS WITH MODERATE HYPERTENSION
Lippert B1, Brüggenjürgen B2, Willich S2
1MERG, Medical Economics Research Group, Munich, Germany;
2 Charité - Universitätsmedizin Berlin, Institut für Sozialmedizin,
Epidemiologie und Gesundheitsökonomie, Berlin, Germany |
|
|
PCV58 |
|
COST-EFFECTIVENESS OF INDAPAMIDE IN PATIENTS WITH
MILD-TO-MODERATE HYPERTENSION
Stafylas PC1, Sarafidis PA1, Lasaridis AN1,
Aletras VH2
1AHEPA University Hospital, Thessaloniki, Greece; 2
University of Macedonia, Thessaloniki, Greece |
|
|
PCV59 |
|
PHARMACO-ECONOMIC ANALYSIS OF
VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ) VERSUS CANDESARTAN/ HCTZ AND VERSUS
TELMISARTAN/HCTZ IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN
MEXICO
Carlos FDJ1, Guzmán JA1, D'ector DM1,
Castillejos C2, Fon F2
1RAC Salud Consultores, S.A. DE C.V, Ciudad de México,
Distrito Federal, Mexico; 2 Novartis, México, México, DF,
Mexico |
|
|
PCV60 |
|
COST-MINIMIZATION ANALYSIS OF TREATMENT OF
MILD-TO-MODERATE HYPERTENSION IN UNITED STATES
Stafylas PC, Sarafidis PA, Lasaridis AN, Zouka MD
AHEPA University Hospital, Thessaloniki, Greece |
|
|
PCV61 |
|
THE FRENCH CV@GOAL EDUCATIONAL PROGRAM FOR IMPROVING
HBP MANAGEMENT BY PATIENTS AND PHYSICIANS: ASSESSMENT OF ITS IMPACT ON
PATIENT'S KNOWLEDGE AND PATIENT-PHYSICIAN RELATIONSHIP
Jasso Mosqueda J1, Poncelet P2, Giacomino A3,
Magar Y4, Chicoye A1, Solesse de Gendre A5,
Lefebvre S5, Beillat M5
1Aremis consultants, Neuilly sur seine, France; 2
Polyclinique de Henin-Beaumont, Henin-Beaumont, France; 3 MG,
Savigny en Veron, France; 4 Edusanté, Vanves, France; 5
PFIZER, Paris, France |
|
|
PCV62 |
|
LIPID PROFILE IN HYPERTENSIVES WITH AND WITHOUT
CARDIOVASCULAR DISEASE: HAS THE HDL COLESTEROL BEEN FORGOTTEN?
Sicras Mainar A1,
F Bobadilla J2, García M3
1Badalona Servicios Asistenciales, Badalona, Spain; 2
Pfizer SA, Alcobendas/Madrid, Spain; 3 Euroclin Institute,
Madrid, Spain |
|
|
PCV63 |
|
CARDIOVASCULAR DRUG USE IN NIS REGION
Kodela BC, Aleksic GS, Milicevic GA, Jovanovic D,
Velickovic-Radovanovic R
City Pharmacy Department of Nis, Nis, Serbia, Serbia and Montenegro |
|
|
PCV64 |
|
HEALTH CARE UTILIZATION OF ANTIHYPERTENSIVE
MEDICATION WITHIN THE SLOVAK REPUBLIC
Tesar T1, Foltan V1, Tomek D2,
Visnansky M1
1Comenius University, Pharmaceutical faculty, Bratislava,
Slovak Republic; 2 Health Insurance Fund Apollo, Bratislava,
Slovak Republic |
|
|
PCV65 |
|
PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS
LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL
HYPERTENSION IN THE MEXICAN HEALTH SECTOR
Guzmán JA1, Carlos F1, Dector D1,
Camacho A1, Fon F2, Castillejos C2
1RAC Salud Consultores, S.A. DE C.V, Ciudad de México,
Distrito Federal, Mexico; 2 Novartis, México, DF, Mexico |
|
|
PCV66 |
|
PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE)
EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY
COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND
POPULATION
Höer A1, Gothe H1, Khan Z2,
Häussler B1
1IGES, Berlin, Germany; 2 Novartis Pharma AG,
Basel, Switzerland |
|
|
PCV67 |
|
FACTORS DETERMINING COMPLIANCE IN PATIENTS WITH HIGH
CARDIOVASCULAR RISK IN DAILY CLINICAL PRACTICE
Sicras Mainar A1,
F Bobadilla J2, Rejas J3
1Badalona Servicios Asistenciales, Badalona, Spain; 2
Pfizer SA, Alcobendas/Madrid, Spain; 3 Pfizer Spain,
Alcobendas/Madrid, Spain |
|
|
PCV68 |
|
COST-EFFECTIVENESS OF RAISING HDL-C WITH
PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED
PATIENTS WITH PERSISTENT DYSLIPIDEMIA IN AUSTRIAN, SWEDISH AND NORWEGIAN
SETTINGS
Roze S1, Valentine WJ1, Palmer AJ1,
Minshall ME2, Liens D3, Renaudin C3
1CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 CORE - USA, LLC, Fishers, IN, USA; 3
Merck Santé, Lyon, France |
|
|
PCV69 |
|
COST-EFFECTIVENESS OF ADD-ON THERAPY WITH
PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED
PATIENTS WITH DYSLIPIDEMIA AND PERSISTENTLY LOW HDL-C IN THE UK AND
GERMANY
Roze S1, Valentine WJ1, Minshall ME2,
Palmer AJ1, Liens D3, Renaudin C3
1CORE - Center for Outcomes Research, Binningen, Basel,
Switzerland; 2 CORE - USA, LLC, Fishers, IN, USA; 3
Merck Santé, Lyon, France |
|
|
PCV70 |
|
WITHDRAWN |
|
|
PCV71 |
|
COST-EFFECTIVENESS OF ROSUVASTATIN COMPARED WITH
GENERIC SIMVASTATIN IN THE UK NHS
Miller PS1, Davies A2, Marotti M3
1AstraZeneca UK, Macclesfield, Cheshire, United Kingdom;
2 Medtap International, London, United Kingdom; 3
Astrazeneca UK, Macclesfield, Cheshire, United Kingdom |
|
|
PCV72 |
|
UTILIZATION PATTERNS OF ASPIRIN AMONG NSAID TREATED
SUBJECTS WITH VARYING CARDIOVASCULAR RISK PROFILES IN A HEALTH BENEFITS
POPULATION
Vanderpoel DR1, Stacy JN1, Hussein MA1,
Bakst AW2
1Humana, Louisville, KY, USA; 2 TAP
Pharmaceuticals, Lake Forest, IL, USA |
|
|
PCV73 |
|
USE OF PROPENSITY SCORE METHODOLOGY IN
CARDIOVASCULAR DEVICE TRIALS: U.S. FOOD AND DRUG ADMINISTRATION
PERSPECTIVES
Muni N, Yue L
U.S. Food and Drug Administration, Rockville, MD, USA |
|
|
PCV74 |
|
A BUDGET IMPACT MODEL FOR EPLERENONE IN THE
TREATMENT OF HEART FAILURE POST MYOCARDIAL INFARCTION
Tabberer M1, Duerden M2
1Pfizer Ltd, Tadworth, Surrey, United Kingdom; 2
Keele University, Keele, Staffordshire, United Kingdom |
|
|
PCV75 |
|
COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI
PATIENTS IN POLAND
Dewilde S1, Opolski G2, Brown R3
1The MEDTAP Institute at UBC, Brussels, Belgium; 2
Medical Academy, Warsaw, Poland; 3 MedTap Institute at UBC,
London, United Kingdom |
|
|
PCV76 |
|
COST-EFFECTIVENESS ANALYSIS OF THE USE OF
ACETYLSALICYLIC ACID COMPARED TO CLOPIDOGREL IN THE SECONDARY PREVENTION
OF PATIENTS WITH PREVIOUS MYOCARDIAL INFRACTION
Pińol C
Q.F. Bayer, S.A, Barcelona, Barcelona, Spain |
|
|
PCV77 |
|
COST AND OUTCOMES AFTER FIRST ACUTE MYOCARDIAL
INFARCTION HOSPITAL ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE
DATABASES
Morsanutto A1, Mantovani L2, Ros B3,
De Portu S2, Spazzapan D3, Tosolini F3
1University of Milan, Milan, Italy; 2 University of
Naples, Naples, Italy; 3 Direzione Regionale della Sanitŕ e
delle Politiche Sociali, Regione Friuli Venezia Giulia, Trieste, Italy |
|
|
PCV78 |
|
THE DIRECT COSTS OF SELECTED CARDIOVASCULAR DISEASES
IN AUSTRIA
Fritz C1, Habacher W1, Jeitler K1,
Seereiner S1, Gfrerer R2, Peter B1,
Pieber T1
1Joanneum Research, Graz, Styria, Austria; 2
Human.technology Styria, Graz, Styria, Austria |
|
|
PCV79 |
|
POSTMYOCARDIAL INFARCTION CARDIAC REHABILITATION IN
LOW RISK PATIENTS. RESULTS WITH A COORDINATED PROGRAM OF CARDIOLOGICAL
AND PRIMARY CARE
Lafuente de Otto V1, Bravo Navas J2,
Montiel Á2, Gómez-Doblas J2, Collantes R2,
González B2, Martínez M2
1Hospital Clinico Universitario Virgen de la Victoria, Málaga,
Malaga, Spain; 2 Hospital Clinico Universitario Virgen de la
Victoria. Centro de Salud de Carranque, Málaga, Malaga, Spain |
|
|
PCV80 |
|
COST ESTIMATION IN PATIENTS WITH AN ATHEROTROMBOTIC
EVENT
Guzmán JA1, Carlos F1, Dector D1,
Guijarro M1, Ortega J2, Galván A3,
Gaxiola E4
1RAC Salud Consultores, S.A. DE C.V, Ciudad de México,
Distrito Federal, Mexico; 2 Hospital Angeles Pedregal, México,
DF, Mexico; 3 Sanofi-Aventis México, México, DF, Mexico;
4 Instituto Cardiovascular de Guadalajara S.A. de C.V.,
Guadalajara, Jalisco, Mexico |
|
|
PCV81 |
|
DISCRETE EVENT SIMULATION OF LONG-TERM HEALTH
BENEFITS AND COST-EFFECTIVENESS OF IMPLANTING DUAL CHAMBER VS. SINGLE
CHAMBER VENTRICULAR PACEMAKERS IN ITALY
Ward AJ, Caro JJ, Deniz HB
Caro Research Institute, Concord, MA, USA |
|
|
PCV82 |
|
COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF
INTERMITTENT CLAUDICATION IN SCOTLAND
Ratcliffe A
Abacus International, Bicester, Oxfordshire, United Kingdom |
|
|
PCV83 |
|
COST-EFFECTIVENESS OF ENDOVASCULAR VERSUS
CONVENTIONAL ABDOMINAL AORTIC ANEURYSM REPAIR AT ONE YEAR; RESULTS OF A
RANDOMIZED TRIAL
Buskens E1, Prinssen M1, Blankensteijn JD
of behalf of the DREAM trial group .2
1University Medical Center Utrecht, Utrecht, Netherlands;
2 Radboud University Nijmegen Medical Center, Nijmegen, Netherlands |
|
|
PCV84 |
|
SURGICAL TREATMENT OF ABDOMINAL AORTIC ANEURISM:
ANALYSIS OF OPERATING COSTS. ENDOVASCULAR TREATMENT VERSUS TRADITIONAL
SURGERY
Palmieri B1, Ponzi P2, Scivales A2,
Puttini M1,
Caprari F2
1Azienda Ospedaliera Ospedale Niguarda Cŕ Granda, Milan,
Italy; 2 Medtronic Italia, Sesto San Giovanni (MI), Italy |
|
|
PCV85 |
|
CLINICAL OUTCOME AND COST-EFFECTIVENESS OF DIFFERENT
BYPASS MATERIALS IN VASCULAR SURGERY
Eidt D1, Roll S2, Vauth C1,
Greiner W3, Willich SN2, Von der Schulenburg J1
1University of Hannover, Hannover, Germany; 2
Charité University Medical Center, Berlin, Germany; 3
Bielefeld University, Bielefeld, Germany |
|
|
PCV86 |
|
THE ECONOMIC BURDEN OF EXPERIENCING MAJOR
COMPLICATIONS DURING PERCUTANEOUS CORONARY INTERVENTION
Long KH, McMurtry EK, Bailey KR, Naessens JM, Jacobson KM, Rihal
CS
Mayo Clinic College of Medicine, Rochester, MN, USA |
|
|
PCV87 |
|
VITAE THROMBOSIS STUDY: THE PREVALENCE AND BURDEN OF
VENOUS THROMBOEMBOLIC DISEASE (VTE) IN EUROPE
Cohen AT, on behalf of the VTE Impact Assessment Group in Europe
(VITAE) X
Guy's, King's and St. Thomas's School of Medicine, London, Greater
London, United Kingdom |
|
|
PCV88 |
|
TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF
INPATIENT THROMBOPROPHYLAXIS IN POLAND
Orlewska E1, Lis J2
1Centre for Pharmacoeconomics, Warsaw, Poland; 2
Sanofi-aventis Poland, Warsaw, Poland |
|
|
PCV89 |
|
COST-EFFECTIVENESS OF AN EXTENDED FOUR-WEEK
FONDAPARINUX PROPHYLAXIS REGIMEN FOR THE PREVENTION OF THROMBOEMBOLIC
EVENTS IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY
Bischof M1, Sendi P1, Leuppi J2
1Institute for Clinical Epidemiology, Basel, Switzerland;
2 Pneumology, Basel University Hospital, Basel, Switzerland |
|
|
PCV90 |
|
COST EFFECTIVENESS OF FONDAPARINUX COMPARED WITH
ENOXAPARIN FOR EXTENDED PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM IN
PATIENTS UNDERGOING HIP FRACTURE SURGERY USING DUTCH ESTIMATES OF COSTS
Van Hout B
Pharmerit BV, Rotterdam, Netherlands |
|
|
PCV91 |
|
COST EFFECTIVENESS OF EXTENDED PROPHYLAXIS WITH
FONDAPARINUX TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP
FRACTURE SURGERY USING UK AND DUTCH ESTIMATES OF COSTS
Van Hout B
Pharmerit BV, Rotterdam, Netherlands |
|
|
PCV92 |
|
HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS
RECEIVING VITAMIN K ANTAGONISTS (VKA): A STUDY USING EQ-5D QUESTIONNAIRE
Monzini M1, Carpenedo M2, Moia M2,
Mantovani LG1
1Center of Pharmacoeconomics, Milan, Italy; 2 IRCCS
Maggiore Hospital and University of Milan, milan, Italy |
|
|
|
|
.........................TOP |
|
ENDOCRINE DISORDERS
|
PED1 |
|
USING EQ-5D TO DERIVE UTILITIES FOR THE QUALITY OF
LIFE-ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA).
Koltowska-Haggstrom M1, Jonsson B2, Isacson
D3, Bingefors K3
1Pfizer Health AB, Stockholm, Sweden; 2 Department
of Women's and Children's Health, Uppsala, Sweden; 3
Department of Pharmacy, Uppsala, Sweden |
|
|
PED2 |
|
LONG-TERM QUALITY OF LIFE (QOL) OUTCOMES IN THE
TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD) – A 5 YEAR
STUDY.
Mattsson A1, Koltowska-Haggstrom M1,
Johannsson G2, Monson JP3, Kind P4
1Pfizer Health AB, Stockholm, Sweden; 2 Sahlgrenska
Academy at Gothenburg's University, Gothenburg, Sweden; 3
William Harvey Research Institute, St Bartholomew's Hospital, Queen Mary
University of London, London, United Kingdom; 4 Uppsala
University, Uppsala, Sweden |
|
|
PED3 |
|
A PROSPECTIVE REAL-LIFE STUDY OF QUALITY OF LIFE IN
PATIENTS WITH ACROMEGALY
Badia X1, Webb S2, Caron P3,
Colao A4, Carvalho D5, Kadioglu P6,
Reincke M7, Pokrajac-Simeunovic A8, Tsagarakis S9,
Johnson I10, Caglio S11, Vincenzi B12
1Health Outcomes Research Europe, Barcelona, Spain; 2
Hospital de la Santa Creu i Sant Pau, Universitat Autňnoma de Barcelona,
Barcelona, Spain; 3 Centre Hospitalier de Rangueil, Toulouse
Cedex, France; 4 Federico II University of Naples, Naples,
Italy; 5 Hospital S. Joao, Porto, Portugal; 6
Cerrahpasa Medical School, Istanbul, Turkey; 7 Klinikum der
Universität München, Munich, Germany; 8 Christie Hospital NHS
Trust, Manchester, United Kingdom; 9 Polikliniki Hospital,
Athens, Greece; 10 Evidence Research Unit, Macclesfield,
Cheshire, United Kingdom; 11 Novartis Pharma SpA, Saronno,
Italy; 12 Novartis Farma S.p.A, Saronno, Italy |
|
|
PED4 |
|
SUSTAINED IMPROVEMENT IN PATIENT-REPORTED OUTCOMES
(PRO) AND NORMALIZATION OF HEALTHCARE UTILIZATION (HCU) DURING GROWTH
HORMONE (GH) REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE
NETHERLANDS
Koltowska-Haggstrom M1, Dorrestijn J2,
Pompen M2, Monteban H2, Mattsson A1,
Koppeschaar HPF3
1Pfizer Health AB, Stockholm, Sweden; 2 Pfizer BV,
Capelle a/d Ijssel, Netherlands; 3 Academic Hospital Utrecht,
Utrecht, Netherlands |
|
|
|
|
.........................TOP |
|
GI DISORDERS
|
PGI1 |
|
CLINICAL OUTCOMES OF RABEPRAZOLE IN PATIENTS WITH
GASTRO-OESOPHAGEAL REFLUX DISEASE IN REAL-WORLD CLINICAL PRACTICE
Haiderali A1, Ferrazzi S1, Fallone C2,
Cohen LB3, Thorp S1, Bartle W3
1Janssen-Ortho, Toronto, ON, Canada; 2 McGill
University, Montreal, QC, Canada; 3 Sunnybrook and Women's
College Health Sciences Centre, Toronto, ON, Canada |
|
|
PGI2 |
|
COST EFFECTIVENESS AND BUDGET IMPACT OF LAMIVUDINE
ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS TYPE B PATIENTS IN TAIWAN
Shau WY1,
Tsai IC2, Scuffham PA3, Dziekan KX4
1GlaxoSmithKline, Singapore, Singapore; 2
GlaxoSmithKline, Taipei, Taiwan; 3 University of Queensland,
Brisbane, Queensland, Australia; 4 GlaxoSmithKline, Greenford,
Middlesex, United Kingdom |
|
|
PGI3 |
|
COST-EFFECTIVENESS OF HELICOBACTER PYLORI TESTING
FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK
Brown GL, Davies S, Phillips CJ
University of Wales Swansea, Swansea, United Kingdom |
|
|
PGI4 |
|
TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN,
A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN DATA
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, Germany |
|
|
PGI5 |
|
THE COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2B
(12KD) PLUS RIBAVIRIN VS. INTERFERON ALFA-2B PLUS RIBAVIRIN FOR CHRONIC
HEPATITIS C (CHC) IN A DEVELOPING COUNTRY - BRAZIL
Fonseca MC, Araujo GTB
Axia.Bio Consulting, Săo Paulo, Brazil |
|
|
PGI6 |
|
ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH
PANTOPRAZOLE IN THE ACUTE AND MAINTENANCE TREATMENT OF REFLUX ESOPHAGITIS
IN FINLAND
Wahlqvist P1, Fernström M2, Määttä P2,
Björholt I3
1AstraZeneca, Mölndal, Sweden; 2 AstraZeneca Oy,
Espoo, Finland; 3 Göteborg University, Gothenburg, Sweden |
|
|
PGI7 |
|
COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD)
(PEGASYS®) COMPARED TO LAMIVUDINE AS FIRST LINE TREATMENT OF CHRONIC
HEPATITIS B (CHB) IN THE UK
Veenstra DL1, Sullivan SD1, Dusheiko GM2,
Jacobs M2, Lewis GJ3, Patel KK4
1University of Washington, Seattle, WA, USA; 2
Royal Free Hampstead NHS Trust, London, London, United Kingdom; 3
Roche Products ltd, Welwyn Garden City, Hertfordshire, United Kingdom;
4 Hoffmann-La Roche, Nutley, NJ, USA |
|
|
PGI8 |
|
ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE
TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
(CD)/ULCERATIVE COLITIS (UC)
Persson U1, Borg S1, Hjelmgren J1,
Ljung T2, Riis L3, Řstergaard Thomsen O3,
Munkholm P3
1IHE, The Swedish Institute for Health Economics, Lund,
Sweden; 2 Karolinska University Hospital, Stockholm, Sweden;
3 Danish Crohn's Colitis Database, Herlev University Hospital,
Copenhagen, Denmark, Copenhagen, Denmark |
|
|
PGI9 |
|
COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC
OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN
Wahlqvist P1, Sörngĺrd H2
1AstraZeneca, Mölndal, Sweden; 2 AstraZeneca,
Södertälje, Sweden |
|
|
PGI10 |
|
WITHDRAWN |
|
|
PGI11 |
|
IBD: INDIRECT COSTS OF ILLNESS AND QUALITY OF LIFE
IN GERMANY
Stark R1, Reitmeir P1, König HH2,
Leidl R1
1GSF - National Research Center for Environment and Health,
Neuherberg (bei München), Germany; 2 University of Leipzig,
Leipzig, Germany |
|
|
PGI12 |
|
THE COSTS OF ACUTE-ON-CHRONIC LIVER FAILURE – A
BOTTOM-UP ANALYSIS BASED ON INDIVIDUAL PATIENT DATA
Hessel FP1, Mitzner S2, Wasem J1
1University of Duisburg-Essen, Essen, NRW, Germany; 2
University of Rostock, Rostock, Germany |
|
|
PGI13 |
|
THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON
WORK PRODUCTIVITY: A SYSTEMATIC REVIEW
Wahlqvist P1, Reilly M2, Barkun A3
1AstraZeneca, Mölndal, Sweden; 2 Margaret Reilly
Associates, Inc, New York, NY, USA; 3 McGill University Health
Centre, Montréal, QC, Canada |
|
|
PGI14 |
|
WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS):
MEASURING DAYS VS HOURS MISSED
Reilly M1,
McBurney C2, Bracco A2
1Margaret Reilly Associates, Inc, New York, NY, USA; 2
Novartis Pharma AG, Basel, Switzerland |
|
|
PGI15 |
|
MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF
CHRONIC HEPATITIS C VIRUS INFECTION (HCVI) IN BRAZIL
Fonseca MC, Araujo GTB
Axia.Bio Consulting, Săo Paulo, Brazil |
|
|
PGI16 |
|
GASTROESOPHAGEAL REFLUX DISEASE (GERD) – PREVALENCE,
MANAGEMENT AND COST IN INTERNATIONAL COMPARISON
Kilgert K1, Lippert B1, Sterzel A2,
Berger K1
1MERG, Medical Economics Research Group, Munich, Germany;
2 ALTANA Pharma AG, Konstanz, Germany |
|
|
PGI17 |
|
ARTIFICIAL LIVER SUPPORT SYSTEMS – A MEDICAL AND
HEALTH ECONOMIC HTA-REPORT
Hessel FP1, Grabein K1, Schnell-Inderst P1,
Siebert U2, Wasem J1
1University of Duisburg-Essen, Essen, NRW, Germany; 2
Harvard Medical School, Boston, MA, USA |
|
|
PGI18 |
|
META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS
REPORTED AT MULTIPLE FOLLOW-UP TIMES
Lu G1, Ades AE1, Sutton AJS2,
Cooper NJ2, Briggs AH3
1University of Bristol, Bristol, United Kingdom; 2
University of Leicester, Leicester, United Kingdom; 3
University of Glasgow, Glasgow, United Kingdom |
|
|
PGI19 |
|
GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE:
ROLE OF NAĎVE AND RELAPSED SYMPTOMS IN GENERAL PRACTICE
Cammarota S1, Mantovani L1, Bruzzese D2,
De Portu S1, Menditto E1, Cuomo R2
1University of Naples, Naples, Italy; 2 University
of Naples, Naples, Naples, Italy |
|
|
PGI20 |
|
ECONOMIC VALUATION MODELING FOR ASSESSING
BIOTECHNOLOGY/PHARMACEUTICAL DEVELOPMENTAL OPPORTUNITIES
Shane LG1, Cox F1, Vernon J2
1Pfizer Inc, New York City, NY, USA; 2 University
of Connecticut, Storrs, CT, USA |
|
|
PGI21 |
|
BURDEN OF ILLNESS OF IBS PATIENTS IN THE NETHERLANDS
Ten Berg MJ1, Goettsch WG1, Van den Boom G2,
Smout AJPM3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht,
Netherlands; 2 Novartis Pharma B.V, Arnhem, Netherlands;
3 University Medical Centre Utrecht, Utrecht, Netherlands |
|
|
PGI22 |
|
BURDEN OF ILLNESS IS HIGHEST IN PATIENTS WITH SEVERE
PAIN SYMPTOMS
Ten Berg MJ1, Goettsch WG1, Siiskonen SJ1,
Van den Boom G2, Smout AJPM3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht,
Netherlands; 2 Novartis Pharma B.V, Arnhem, Netherlands;
3 University Medical Centre Utrecht, Utrecht, Netherlands |
|
|
PGI23 |
|
ESOMEPRAZOLE TREATMENT IN PATIENTS WITH
UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN
PRODUCTIVITY WHILE AT WORK AND IN DAILY ACTIVITIES – RESULTS FROM A
RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY
Wahlqvist P1, Bergenheim K1, Persson T2,
Brun J3, Flook N4, Lauritsen K5, Vakil N6,
Veldhuyzen van Zanten S7, Talley NJ8
1AstraZeneca, Mölndal, Sweden; 2 AstraZeneca, Lund,
Sweden; 3 AstraZeneca, Södertälje, Sweden; 4
University of Alberta, Edmonton, Alberta, Canada; 5 Odense
University Hospital, Odense, Denmark; 6 University of
Wisconsin Medical School, Milwaukee, WI, USA; 7 Dalhousie
University, Halifax, Nova Scotia, Canada; 8 Mayo Clinic
College of Medicine, Rochester, MN, USA |
|
|
|
|
.........................TOP |
|
HEMATOLOGICAL DISORDERS
|
PHM1 |
|
COST-EFFECTIVENESS OF REGULAR CONTINUOUS
PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A
Monzini M1, Gringeri A2, Ravera S1,
Mantovani LG1
1Center of Pharmacoeconomics, Milan, Italy; 2
Haemophilia and Thrombosis Centre, Milan, Italy |
|
|
PHM2 |
|
THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT
INHIBITORS: THE COCHE STUDY
Mantovani LG1, Scalone L1, Mannucci PM2,
Anastasia M1, De Silvio S1, Di Stasi F1,
Gringeri A2
1Center of Pharmacoeconomics, University of Milan, Milan,
Italy; 2 Haemophilia and Thrombosis Centre, Milan, Italy |
|
|
PHM3 |
|
COSTS OF HAEMOPHILIA ASSISTANCE IN ROMANIA
Mihailov MD1, Serban M2, Schramm W3,
Lippert B4, Arghirescu S5
1University of Medicine, Timisoara, Timis, Romania; 2
University of Medicine, Timisoara, Romania; 3 Ludwig
Maximilians University, Munich, Munich, Germany; 4 MERG,
Medical Economics Research Group, Munich, Germany; 5
University of Medicine "Victor Babes" Timisoara, Romania, Timisoara,
Timis, Romania |
|
|
PHM4 |
|
UK COST COMPARISON OF BUCY2 CONDITIONING IN
ALLOGENEIC HSCT: ORAL VERSUS IV BUSULFAN (BUSILVEX®)
Groves LJ1, Hill S2, Nichol A2,
Myon E3, Orchard KH1
1Southampton General Hospital, Southampton, Hampshire,
England; 2 Pierre Fabre Ltd, Winchester, Hampshire, England;
3 Pierre Fabre SA, Boulogne Billancourt, France |
|
|
PHM5 |
|
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC
INSTRUMENT HAEM-A-QOL
Von Mackensen S1, Scalone L2, Ravera S2,
Mantovani L2, Gringeri A3
1Institute for Medical Psychology, Hamburg, Germany; 2
Center of Pharmacoeconomy, Milan, Italy; 3 Haemophilia and
Thrombosis Centre, Milan, Italy |
|
|
PHM6 |
|
ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN
ADULT PATIENTS WITH HAEMOPHILIA A SWITCHED TO PROPHYLACTIC REPLACEMENT
TREATMENT
Ravera S1, Monzini M1, Gringeri A2,
Mantovani LG1
1Center of Pharmacoeconomics, Milan, Italy; 2
Haemophilia and Thrombosis Centre, Milan, Italy |
|
|
PHM7 |
|
DISEASE STATE AND QUALITY OF LIFE IN PATIENTS WITH
MYELODYSPLASTIC SYNDROMES: A REVIEW OF INSTRUMENTS, DISEASE BURDEN, AND
PREDICTIVE FACTORS FOR OUTCOMES
Szende A1, Wang M2, Husbands C3,
Schaefer C3, Goss TF3
1Covance Health Economics and Outcomes Services, Leeds, West
Yorkshire, United Kingdom; 2 Celgene Corporation, Sumit, NJ,
USA; 3 Covance Health Economics and Outcomes Services,
Gaithersburg, MD, USA |
|
|
PHM8 |
|
THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON
THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON OVERLOAD (IO)
Abetz L1, Jones P2, Baladi JF2
1Mapi Values, Macclesfield, Cheshire, United Kingdom; 2
Novartis Pharmaceutical Corporation, East Hanover, PA, USA |
|
|
PHM9 |
|
HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH
THEIR TREATMENT
Von Mackensen S1, Scalone L2, Mantovani L2,
Gringeri A3
1Institute for Medical Psychology, Hamburg, Germany; 2
Center of Pharmacoeconomy, Milan, Italy; 3 Haemophilia and
Thrombosis Centre, Milan, Italy |
|
|
|
|
.........................TOP |
|
NEUROLOGICAL DISORDERS
|
PNL1 |
|
EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV
MODEL ESTIMATING THE COST EFFECTIVENESS OF MEMANTINE VERSUS STANDARD CARE
IN ALZHEIMER DISEASE FROM A UK PERSPECTIVE
Guilhaume C1, Rive B2, Francois C1,
Livingston G3, Katona C4
1Lundbeck SA, Paris, France; 2 Altipharm SA, Paris,
France; 3 University College London, London, United Kingdom;
4 University of Kent, Canterbury, United Kingdom |
|
|
PNL2 |
|
COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT TO
PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL IN THE UNITED KINGDOM
Guilhaume C1, Rive B2, Cochran J1
1Lundbeck SA, Paris, France; 2 Altipharm SA, Paris,
France |
|
|
PNL3 |
|
RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA
MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE
PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE.
Sicras A1, Vergara J2, León T3,
Febrer L4, Rejas J3
1Badalona Servicios Asistenciales,SA, Badalona, Barcelona,
Spain; 2 Health Center, Benahadux, Almería, Spain; 3
Pfizer Spain, Alcobendas, Madrid, Spain; 4 SALUTIS RESEARCH,
S.L, Barcelona, Barcelona, Spain |
|
|
PNL4 |
|
THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC
EPILEPSY IN IRELAND: A PROSPECTIVE STUDY
McGinn M1, Najam Y2, Deiratany S2, Grant
D3, Sawyer W3, Reeves P3,
Hughes J4, Webb D1, McMenamin J1
1Our Lady's Hospital for Sick Children, Crumlin, Dublin,
Ireland; 2 Royal College of Surgeons in Ireland, Dublin,
Dublin County, Ireland; 3 Fourth Hurdle Consulting Ltd,
London, United Kingdom; 4 GlaxoSmithKline Ireland, Dublin,
Ireland |
|
|
PNL5 |
|
A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S
EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY
Deiratany S1, Najam Y1, Grant D2, Sawyer
W2,
Hughes J3, McMenamin J4, Webb D4,
Reeves P2
1Royal College of Surgeons in Ireland, Dublin, Dublin County,
Ireland; 2 Fourth Hurdle Consulting Ltd, London, United
Kingdom; 3 GlaxoSmithKline Ireland, Dublin, Ireland; 4
Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland |
|
|
PNL6 |
|
THE EPIDEMIOLOGY AND MANAGEMENT OF MIGRAINE IN THE
UK
Quilici S1, Cure S1, Martin M1,
Odeyemi IA2
1Innovus Research (UK) Ltd, High Wycombe, United Kingdom;
2 Allergan Ltd, High Wycombe, United Kingdom |
|
|
PNL7 |
|
IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS
EFFICIENT FROM A SOCIETAL PERSPECTIVE?
Gracia-Naya M1, Díaz S2, Latorre A1,
Rejas J3
1Miguel Servet Hospital, Zaragoza, Zaragoza, Spain; 2
Euriclin Institute, Madrid, Madrid, Spain; 3 Pfizer Spain,
Alcobendas/Madrid, Spain |
|
|
PNL8 |
|
COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR
VERTIGO
Avksentieva M, Vorobyov P, Leontiev S, Soura M, Morozova S,
Yakhno N, Bojko A
Moscow medical academy, Moscow, Russia |
|
|
PNL9 |
|
COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION
POLICIES IN SOUTH AFRICA
Griffiths UK1, Botham L2, Schoub BD3
1Muusmann Research and Consulting, Kolding, Denmark; 2
Department of Health, Pretoria, South Africa; 3 National
Institute for Communicable Diseases, Sandringham, South Africa |
|
|
PNL10 |
|
THE COSTS OF INFORMAL CARE IN NEUROLOGICAL DISORDERS
IN SPAIN
Oliva J1, Osuna R2, Lobo F1,
Cabańa M1, León T3, Rejas J3
1University Carlos III of Madrid, Getafe, Madrid, Spain;
2 UNED, Madrid, Spain; 3 Pfizer Spain, Alcobendas,
Madrid, Spain |
|
|
PNL11 |
|
A REVIEW OF THE ECONOMIC EVIDENCE FOR BOTULINUM
TOXINS IN SPASTICITY ASSOCIATED WITH STROKE AND CEREBRAL PALSY
Richard LJ1, Odeyemi IA2, Ward AB3
1Heron Group, Letchworth Garden City, Herts, United Kingdom;
2 Allergan Ltd, High Wycombe, United Kingdom; 3
North Staffordshire Rehabilitation Centre, Stoke-on-Trent, Staffordshire,
United Kingdom |
|
|
PNL12 |
|
A RETROSPECTIVE STUDY OF DRUG TREATMENT PATTERNS
AMONGST UK PRIMARY CARE PATIENTS WITH RESTLESS LEGS SYNDROME (RLS)
BETWEEN 1ST APRIL 2004 AND 31ST MARCH 2005
Das Gupta R1, Chaudhuri K2
1Boehringer Ingelheim, Bracknell, Berkshire, United Kingdom;
2 King's College Hospital, London, United Kingdom |
|
|
PNL13 |
|
IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR) A
MEDICAL DEVICE AND PATIENT REGISTRY
Stoker V, Weaver T, Hargens L
Medtronic, Minneapolis, MN, USA |
|
|
PNL14 |
|
USE OF THE SELF-ADMINISTERED NEUROPATHY TOTAL
SYMPTOM SCORE – 6 (NTSS-6 SA) IN AN INTERNATIONAL STUDY
Mear I1, Grataloup G1, Nadjar A1,
Seignobos E2, Trudeau E2, Bastyr E3
1Mapi Research Institute, Lyon, Rhone, France; 2
Mapi Values, Lyon, Rhone, France; 3 ELI LILLY, Indianapolis,
IN, USA |
|
|
PNL15 |
|
PREFERENCE FOR RECONSTRUCTIVE INTERVENTIONS OF THE
UPPER EXTREMITIES IN TETRAPLEGIA: THE IMPACT OF TREATMENT CHARACTERISTICS
IJzerman MJ1, Snoek GJ1, van Til JA1,
Krabbe PF2
1University of Twente/Roessingh Research and Development,
Enschede, Overijssel, Netherlands; 2 Radboud University
Nijmegen Medical Centre, Nijmegen, Netherlands |
|
|
PNL16 |
|
THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY
Colombo GL1, Antonini A2, Guerra PU3,
Dondi M4
1SAVE, Milano, Italy; 2 Istituti Clinici di
Perfezionamento, Milan, Italy; 3 Ospedali Riuniti di Bergamo,
Bergamo, Italy; 4 Ospedale Maggiore, Bologna, Italy |
|
|
PNL17 |
|
A COST-UTILITY MODEL COMPARING AZILECT® (RASAGILINE)
WITH STANDARD CARE AND ENTACAPONE IN THE TREATMENT OF PARKINSONIAN
PATIENTS WITH MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
Hudry J1, Rinne J2, Keränen T3,
Eckert L1, Cochran J1, François C1
1H. Lundbeck A/S, Paris, France; 2 University of
Turku, Turku, Finland; 3 Tampere University Hospital, Tampere,
Finland |
|
|
PNL18 |
|
COST-EFFECTIVENESS OF CONTINUOUS DUODENAL DELIVERY
OF LEVODOPA (DUODOPA®) IN PATIENTS WITH SEVERE PARKINSON'S DISEASE
Kristiansen IS1, Bingefors K2, Isacson D2
1University of Oslo, Oslo, Norway; 2 Department of
Pharmacy, Uppsala, Sweden |
|
|
PNL19 |
|
META-ANALYSIS OF CASE SERIES TO PROVIDE INPUTS FOR A
DISCRETE EVENT SIMULATION OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF
PARKINSON'S DISEASE
Caro JJ1, Caro I2, Ishak KJ2,
Proskorovsky I2
1Caro Research Institute, Concord, MA, USA; 2 Caro
Research Institute, Montreal, QC, Canada |
|
|
PNL20 |
|
DISEASE SEVERITY AND HEALTH CARE COSTS OF
RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
Mateus C,
Pereira J
Universidade Nova de Lisboa, Lisboa, Lisboa, Portugal |
|
|
PNL21 |
|
THE COST OF MULTIPLE SCLEROSIS (MS) IN EUROPE
Berg J1, Kobelt G2, Lindgren P1,
Fredrikson S3, Jönsson B4
1Stockholm Health Economics, Stockholm, Sweden; 2
European Health Economics, Speracedes, France; 3 Karolinska
University Hospital, Stockholm, Sweden; 4 Stockholm School of
Economics, Stockholm, Sweden |
|
|
PNL22 |
|
THE SYMPTOMATIC, FUNCTIONAL AND QUALITY OF LIFE
IMPACT OF MULTIPLE SCLEROSIS. REPORT ON A QUALITATIVE INVESTIGATION OF
THE PATIENTS' PERSPECTIVE
Doward LC1, McKenna SP2, Meads DM2,
Kavyasiddhi D2, Hampson NE2, Mayo KW3
1Galen Research, Manchester, United Kingdom; 2
Galen Research, Manchester, Manchester, United Kingdom; 3
Novartis Pharma AG, Basel, Basel, Switzerland |
|
|
|
|
.........................TOP |
|
OSTEOPOROSIS
|
POS1 |
|
SYSTEMATIC REVIEW OF IBANDRONATE FOR POSTMENOPAUSAL
OSTEOPOROSIS
Schnitzer TJ1, Stephenson JJ2, Chen YT3,
Sen SS4, Long S2, Abbott T2
1Northwestern University Feinberg School of Medicine, Chicago,
IL, USA; 2 Thomson Medstat, Philadelphia, PA, USA; 3
Merck & Co., Inc, West Point, PA, USA; 4 Merck & Co., Inc,
Whitehouse Station, NJ, USA |
|
|
POS2 |
|
CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY
FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES: A SYSTEMATIC REVIEW
OF THE LITERATURE
Taylor RS1, Rebecca J T1, Frtizell P2
1University of Birmingham, Birmingham, United Kingdom; 2
Falun Hospital, Falun, Sweden |
|
|
POS3 |
|
RISK FOR OSTEOPOROTIC FRACTURES IS REDUCED IN
PERSISTENT BISPHOSPHONATE USERS
Goettsch WG1, Penning-van Beest FJ1, Erkens
JE1, Lynch NO2, Novak A3, Herings RMC1
1PHARMO Institute for Drug Outcomes Research, Utrecht,
Netherlands; 2 GlaxoSmithKline, Greenford, Middlesex, United
Kingdom; 3 Roche Nederland B.V, Woerden, Netherlands |
|
|
POS4 |
|
COST-EFFECTIVENESS OF PREVENTION OF
GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE OR ALFACALCIDOL. THE
STOP-STUDY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
De Nijs R.,
Buskens E, Jacobs JW, Bijlsma JWJ on behalf of the STOP study
group .
University Medical Center Utrecht, Utrecht, Netherlands |
|
|
POS5 |
|
THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO
ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS: A
POLISH ANALYSIS
Orlewska E1, Lis J2, Gierczynski J3
1Centre for Pharmacoeconomics, Warsaw, Poland; 2
Sanofi-aventis Poland, Warsaw, Poland; 3 sanofi-aventis group,
Warsaw, Poland |
|
|
POS6 |
|
IMPACT OF BISPHOSPHONATES ON OSTEOPOROTIC FRACTURES,
PATIENT QUALITY OF LIFE AND TREATMENT COSTS: THE CASE OF GERMANY
Kruse HP1, Kurth A2, Moehrke W3,
Lyssy A4, Pasquale M5, Grima D6
1Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany;
2 University of Frankfurt, Frankfurt am Main, Germany; 3
Procter & Gamble Pharmaceuticals, Schwalbach am Taunus, Germany; 4
Procter & Gamble Pharmaceuticals, Schwalbach a. Ts, Germany; 5
Procter & Gamble Pharmaceuticals, Mason, OH, USA; 6
Cornerstone Research Group Inc, Oakville, ON, Canada |
|
|
POS7 |
|
EVALUATION OF DISTRIBUTION OF HIP REPLACEMENT IN
HUNGARY ACCORDING TO GEOGRAPHICAL REGIONS AND AGE GROUPS
Sebestyen A1, Boncz I2,
David T2, Vermes C3
1National Health Insurance Fund Administration (OEP), Pécs,
Hungary; 2 National Health Insurance Fund Administration
(OEP), Budapest, Hungary; 3 University of Pécs, Pécs, Hungary |
|
|
POS8 |
|
CONTENT VALIDATION OF OSTEOPOROSIS TREATMENT
PREFERENCE QUESTIONNAIRE
Flood E1, Hebborn A2, Beusterien K1
1The MEDTAP Institute at UBC, Bethesda, MD, USA; 2
F. Hoffmann-La Roche AG, Basel, Switzerland |
|
|
POS9 |
|
EXTENDING THE BURDEN OF DISEASE PROTOCOL: DERIVING
DISABILITY WEIGHTS FOR RISK FACTOR DISEASES - THE CASE FOR OSTEOPOROSIS
Janssen M, Birnie E, Bonsel G
Academic Medical Center, Amsterdam, Noord-Holland, Netherlands |
|
|
POS10 |
|
PERSISTENCE OF DRUG TREATMENT WITH ALENDRONATE AND
RISEDRONATE IN PRIMARY CARE PATIENTS
Moehrke W1, Lyssy A1, Wick B2,
Gerd M2
1Procter & Gamble Pharmaceuticals, Schwalbach, Germany; 2
Procter & Gamble Pharmaceuticals, Schwalbach a. Ts, Germany |
|
|
POS11 |
|
AN INTERNATIONAL COMPARISON OF THE IMPACT OF DOSING
FREQUENCY ON COMPLIANCE AND PERSISTENCE WITH BISPHOSPHONATE THERAPY,
AMONG POST-MENOPAUSAL WOMEN IN THE US, UK AND GERMANY
Cramer JA1, Lynch NO2, Walker M3,
Cowell W3, Suppapanya N4, Rigney U2,
Hammerschmidt T5
1Yale University School of Medicine, West Haven, CT, USA;
2 GlaxoSmithKline, Greenford, Middlesex, United Kingdom; 3
Roche Products Ltd, Welwyn Garden City, Hertfordshire, United Kingdom;
4 GlaxoSmithKline, Collegeville, PA, USA; 5
GlaxoSmithKline, Munich, Bavaria, Germany |
|
|
POS12 |
|
HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL
WOMEN WITH OSTEOPOROSIS AND AN INADEQUATE RESPONSE TO ANTI-OSTEOPOROSIS
MEDICATION: BASELINE RESULTS OF THE FRENCH COHORT FROM THE OBSERVATIONAL
STUDY OF SEVERE OSTEOPOROSIS (OSSO)
Fardellone P1, Liu-Leage S2,
Alfonsi A2, Tcherny-Lessenot S2
1CHRU Amiens, Amiens, France; 2 Lilly France,
Suresnes, France |
|
|
POS13 |
|
UNDERSTANDING AND ASSESSING TIBIA FRACTURE ON
QUALITY OF LIFE ; CONCEPTUAL MODEL AND NEW DISEASE SPECIFIC HR-QOL
MEASURE
Brod M1, Lammert M2
1The BROD GROUP, Mill Valley, CA, USA; 2 Novo
Nordisk, Bagsvaerd, Denmark |
|
|
POS14 |
|
ELICITING AND QUANTIFYING PATIENT PREFERENCES FOR
DOSING FREQUENCY
Walker M1, Carr AJ2, Cowell W1
1Roche Products Ltd, London, London, United Kingdom; 2
Clinimatrix Limited, London, London, United Kingdom |
|
|
|
|
.........................TOP |
|
PAIN
|
PPN1 |
|
COGNITIVE FUNCTION IMPAIRMENT IN PATIENTS WITH NEUROPATHIC PAIN
Povedano M1, Gascón J1, Gálvez R2, Ruíz
M3,
Rejas J3
1Principes de Espańa Hospital, L´Hospitalet de Llobregat,
Barcelona, Spain; 2 Virgen de las Nieves Hospital, Granada,
Spain; 3 Pfizer Spain, Alcobendas, Madrid, Spain |
|
|
PPN2 |
|
THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-RELEASE
OPIOIDS FOR THE TREATMENT OF CHRONIC NON-MALIGNANT PAIN: A PROBABILISTIC
DECISION-MODEL
Hawkins N1, Sculpher M1, Morris J2
1Unversity of York, York, United Kingdom; 2 Napp
Pharmaceuticals, Cambridge, United Kingdom |
|
|
PPN3 |
|
BURDEN OF ILLNESS OF PATIENTS WITH NEUROPATHIC PAIN
IN PRIMARY CARE IN THE UNITED KINGDOM
Makinson GT, Koncz TA
Pfizer Ltd, Tadworth, United Kingdom |
|
|
PPN4 |
|
DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP) MEDICAL
MANAGEMENT ACCORDING TO AETIOLOGY: RESULTS OF THE REC STUDY
Rodríguez M1, Garcia A2, Rejas J3
1University Hospital Carlos Haya, Málaga, Spain; 2
Universidad de Málaga, Málaga, Spain; 3 Pfizer Spain,
Alcobendas, Madrid, Spain |
|
|
PPN5 |
|
A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICATM(PREGABALIN)
VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN
Annemans L1, Caekelbergh K1, Hans G2,
Marbaix S3
1IMS Health, Brussels, Belgium; 2 University of
Antwerp, Antwerp, Belgium; 3 Pfizer, Brussels, Belgium |
|
|
PPN6 |
|
A UK PHARMACOECONOMIC MODEL OF PARENTERAL PARECOXIB
VERSUS OPIOID ANALGESIA FOLLOWING MAJOR SURGERY
Miller JD1, Russell MW1, Neumann PJ2,
Menzin J1, Boye ME3, Rublee DA4
1Boston Health Economics, Inc, Waltham, MA, USA; 2
Harvard School of Public Health, Boston, MA, USA; 3 Pfizer
Inc, Ann Arbor, MI, USA; 4 Pfizer Inc, New York, NY, USA |
|
|
PPN7 |
|
COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION
TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR
POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS
Nuijten MJ1,
Poulsen Nautrup B2
1Erasmus University, Rotterdam, Netherlands; 2
Gruenenthal GmbH, Aachen, Germany |
|
|
PPN8 |
|
THE MOS-SHORT-FORM-12 (SF-12) AS A MEASURE OF
HEALTH-RELATED QUALITY OF LIFE IN NEUROPATHIC PAIN (NEP) PATIENTS:
RELIABILITY, CONCURRENT AND DISCRIMINANT VALIDITY.
Rejas J1, Masramon X2, Ruíz M3
1Pfizer Spain, Alcobendas/Madrid, Spain; 2 Euroclin
Institute, Barcelona, Barcelona, Spain; 3 Pfizer Spain,
Alcobendas, Madrid, Spain |
|
|
PPN9 |
|
HEALTH STATUS AS MEASURED BY PATIENT UTILITY
DETERMINATION AMONG PATIENTS WITH PAIN: RESULTS FROM A CROSS-SECTIONAL
SURVEY.
Pérez C1, Gálvez R2, Insausti J3,
Martínez-Valero C2, Ruíz M4, González P4,
Díaz S5,
Rejas J4
1La Princesa Hospital, Madrid, Madrid, Spain; 2
Virgen de las Nieves Hospital, Granada, Granada, Spain; 3
Severo Ochoa Hospital, Leganés, Madrid, Spain; 4 Pfizer Spain,
Alcobendas, Madrid, Spain; 5 Euriclin Institute, Madrid,
Madrid, Spain |
|
|
PPN10 |
|
PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN
NEUROPATHIC PAIN (NEP) SYNDROMES.
Rejas J1, Ribera MV2, Ruíz M1,
Masramon X3
1Pfizer Spain, Alcobendas, Madrid, Spain; 2
Hospital Vall d´Hebrón, Barcelona, Barcelona, Spain; 3
Euroclin Institute, Barcelona, Barcelona, Spain |
|
|
|
|
.........................TOP |
|
SKIN
|
PSN1 |
|
USING THE GENERAL PRACTICE RESEARCH DATABASE TO
ESTIMATE THE INCIDENCE, PREVALENCE AND MANAGEMENT OF HYPERHIDROSIS IN THE
UNITED KINGDOM
Brown B1, Odeyemi IA2, Christova L1,
Aristides M1, Tilden D1
1M-TAG, a division of IMS Health Economics and Outcomes
Research, London, United Kingdom; 2 Allergan Ltd, High
Wycombe, United Kingdom |
|
|
PSN2 |
|
COST-EFFECTIVENESS ANALYSIS: ALDARATM
(IMIQUIMOD) CREAM, 5% IN THE TREATMENT OF SUPERFICIAL BASAL CELL
CARCINOMA IN NORWAY
Sverre JM1, Kristensen F1,
Hamel-Gariépy L2, Albrektsen T3
1PharmEcon AS, Asker, Norway; 2 Laboratoires 3M
Santé, Cergy-Pontoise, France; 3 3M Pharma, Skjetten, Norway |
|
|
PSN3 |
|
ECONOMIC EVALUATION OF PIMECROLIMUS, A NEW TREATMENT
OF CHILDREN WITH ATOPIC DERMATITIS IN HUNGARY
Kósa J
Novartis Hungary, Budapest, Pest, Hungary |
|
|
PSN4 |
|
COST-EFFECTIVENESS MODEL OF ALDARATM
(IMIQUIMOD) CREAM, 5% IN SUPERFICIAL BASAL CELL CARCINOMA IN THE
NETHERLANDS
De Cock E1, Nuijten M2, Hollestein A3,
Hamel-Gariépy L4
1The Medtap Institute, London, United Kingdom; 2
Erasmus University, Rotterdam, Netherlands; 3 3M Pharma,
Zoeterwoude, Netherlands; 4 Laboratoires 3M Santé,
Cergy-Pontoise, France |
|
|
PSN5 |
|
WITHDRAWN |
|
|
PSN6 |
|
COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO
ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN GERMANY
Kaltwasser MT1, Nannicini A2, Tofani L2
1Berlin-Chemie (Menarini Group), Berlin, Germany; 2
A. Menarini, Florence, Italy |
|
|
PSN7 |
|
EPIDEMIOLOGY AND MANAGEMENT OF EXTERNAL GENITAL
WARTS (EGW) IN FRANCE
Vainchtock A1, Aractingi S2, Monsonego J3,
Sultan S4, Vernay C5, Duru G6, Decuypere
L7, Flahault A8, Lamarsalle L1,
Hamel-Gariépy L7
1IMS Health - GYD institut, Lyon, France; 2 Hôpital
Tenon, Paris, France; 3 Institut Alfred Fournier, Paris,
France; 4 Hôpital des Diaconesses, Paris, France; 5
DAV - Conseil Général des Bouches du Rhône, Marseilles, France; 6
Universite Claude Bernard Lyon I, Lyon, France; 7 Laboratoires
3M Santé, Cergy-Pontoise, France; 8 INSERM - Unité 707, Paris,
France |
|
|
PSN8 |
|
EXAMINATION OF ADHERENCE TO PHARMACOTHERAPY
TREATMENT GUIDELINES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES
Kulkarni A1, Horn E2, Balkrishnan R1,
Feldman S3
1Ohio State University College of Pharmacy, Columbus, OH, USA;
2 National Psoriasis Foundation, Portland, OR, USA; 3
Wake Forest University School of Medicine, Winston Salem, NC, USA |
|
|
PSN9 |
|
PATTERNS OF TOPICAL ACNE PRESCRIPTION MEDICATION
USE: ANALYSIS OF A LARGE-SCALE RETROSPECTIVE CLAIMS DATABASE
Hankin C1, Patel BV2, Leslie S2,
Gyang E1
1BioMedEcon, LLC, Moss Beach, CA, USA; 2 MedImpact
Healthcare Systems, Inc, San Diego, CA, USA |
|
|
PSN10 |
|
THE RISE OF THE GENERIC DRUG MARKET: IMPLICATIONS
FOR THE TREATMENT OF SKIN DISEASES
Bhosle M1, Balkrishnan R1, Feldman S2
1Ohio State University College of Pharmacy, Columbus, OH, USA;
2 Wake Forest University School of Medicine, Winston Salem,
NC, USA |
|
|
PSN11 |
|
PREDICTORS OF HEALTH CARE OUTCOMES AND COSTS RELATED
TO MEDICATION USE IN PATIENTS WITH ACNE IN THE UNITED STATES
Balkrishnan R1, Kulkarni A1, Feldman S2
1Ohio State University College of Pharmacy, Columbus, OH, USA;
2 Wake Forest University School of Medicine, Winston Salem,
NC, USA |
|
|
PSN12 |
|
NAIL PSORIASIS: ELABORATION OF A SCALE FOR
FUNCTIONAL DISCOMFORT
Taieb C1, Corvest M2, Voisard J3,
Marionneau N1, Myon E1
1Pierre Fabre, Boulogne-Billancourt, France; 2
APLCP, Vannes, France; 3 Pierre Fabre Dermatologie, Lavaur,
France |
|
|
PSN13 |
|
REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS
QUESTIONNAIRE: CLASSICAL TEST THEORY VS RASCH ANALYSIS
Nijsten T1, Unaeze J2, Stern RS3
1University Hospital of Antwerp, Edegem, Belgium; 2
Harvard medical school, Boston, MA, USA; 3 Beth Isreal
Deaconess Medical Center, Harvard Medical school, Boston, MA, USA |
|
|
PSN14 |
|
CHANGES IN FUNCTIONAL ABILITY AS MEASURED BY DLQI IS
CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS
PATIENTS TREATED WITH ADALIMUMAB
Melilli LE1, Shikiar R2, Thompson C3
1Abbott Laboratories, Abbott Park, IL, USA; 2
MEDTAP Institute at United Biosource Corporation, Seattle, WA, USA;
3 MEDTAP Institute at United Biosource Corporation, Bethesda, MD,
USA |
|
|
PSN15 |
|
QUALITY OF LIFE IMPROVEMENT AS MEASURED BY EQ-5D IS
CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS
PATIENTS TREATED WITH ADALIMUMAB
Melilli LE1, Shikiar R2, Thompson C3
1Abbott Laboratories, Abbott Park, IL, USA; 2
MEDTAP Institute at United Biosource Corporation, Seattle, WA, USA;
3 MEDTAP Institute at United Biosource Corporation, Bethesda, MD,
USA |
|
|
PSN16 |
|
NAIL PSORIASIS: IMPACT ON QUALITY OF LIFE
Taieb C1, Corvest M2, Voisard J3,
Marionneau N1, Myon E1
1Pierre Fabre, Boulogne-Billancourt, France; 2
APLCP, Vannes, France; 3 Pierre Fabre Dermatologie, Lavaur,
France |
|
|
PSN17 |
|
VALIDATION OF THE ITALIAN VERSION OF THE INFANTS'
DERMATITIS QUALITY OF LIFE & FAMILY DERMATITIS INDEXES
Baranzoni N1, Scalone L2, Rigoni L3,
Mantovani LG2, Giannetti A1
1Divisione Clinica Dermatologica, Modena, Italy; 2
Center of Pharmacoeconomics, University of Milan, Milan, Italy; 3
Fujisawa Srl, Milan, Italy |
|
|
PSN18 |
|
ATOPIC DERMATITIS: IMPACT ON SEXUALITY
Taieb C, Marionneau N, Myon E
Pierre Fabre, Boulogne-Billancourt, France |
|
|
PSN19 |
|
QUALITY OF LIFE OF PAEDIATRIC PATIENTS WITH ATOPIC
ECZEMA AND THEIR FAMILIES
Scalone L1, Gelmetti C2, De Portu S3,
Monzini M1, Colonna C2, De Silvio S1,
Mantovani LG1
1Center of Pharmacoeconomics, Milan, Italy; 2
Department of Internal Medicine and Dermatology, University of Milan,
Milan, Italy; 3 University of Naples, Naples, Italy |
|
|
PSN20 |
|
VALIDATION OF THE ITALIAN VERSION OF THE DERMATOLOGY
LIFE QUALITY INDEX
Baranzoni N1, Scalone L2, Rigoni L3,
Mantovani LG2, Giannetti A1
1Divisione Clinica Dermatologica, Modena, Italy; 2
Center of Pharmacoeconomics, University of Milan, Milan, Italy; 3
Fujisawa Srl, Milan, Italy |
|
|
PSN21 |
|
IMPACT OF CORTICOSTEROID-SPARING EFFECT OF AN
EMOLLIENT MILK ON FAMILY'S QUALITY OF LIFE OF INFANTS AFFECTED BY ATOPIC
DERMATITIS
Myon E1, Durosier V2, Sibaud V2,
Marionneau N1, Taďeb C1
1Pierre Fabre, Boulogne-Billancourt, France; 2
Ducray - Aderma, Lavaur, France |
|
|
PSN22 |
|
SENSITIVE SKIN: IMPACT ON QUALITY OF LIFE
Misery L1, Myon E2, Marionneau N2,
Taieb C2
1CHU Brest, Brest, France; 2 Pierre Fabre,
Boulogne-Billancourt, France |
|
|
PSN23 |
|
FACTORS INFLUENCING QUALITY OF LIFE IN ATOPIC
DERMATITIS
Hampson NE1,
Meads DM1, McKenna SP1, Doward LC1,
Turk F2
1Galen Research, Manchester, Manchester, United Kingdom;
2 Novartis Pharma AG, Basel, Switzerland |
|
|
PSN24 |
|
ATOPIC DERMATITIS: A CONJOINT ANALYSIS PILOT STUDY
Monzini M1, Gelmetti C2, De Portu S3,
Scalone L1, De Silvio S4, Colonna C2,
Mantovani L5
1Center of Pharmacoeconomics, Milan, Italy; 2
Department of Internal Medicine and Dermatology, University of Milan,
Milan, Italy; 3 University of Naples, Naples, Italy; 4
Center of Pharmacoeconomics, University of Milan, Milan, Italy; 5
Center of Pharmacoeconomy, Milan, Italy |
|
|
PSN25 |
|
ADULTS WITH ATOPIC DERMATITIS: QUALITY OF LIFE
IMPACT
Taieb C, Marionneau N, Myon E
Pierre Fabre, Boulogne-Billancourt, France |
|
|
|
|
.........................TOP |
|
STROKE
|
PST1 |
|
PREDICTORS OF STROKE RISK ASSOCIATED WITH ATRIAL
FIBRILLATION: RESULTS FROM A LARGE COMMERCIALLY INSURED US POPULATION
Ollendorf D1, Fidan D2, Leguet P2,
Gabriel S2, Boccuzzi SJ1
1PharMetrics, Inc, Watertown, MA, USA; 2
Sanofi-Aventis, Bagneux Cedex, France |
|
|
PST2 |
|
COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH
HYPERTENSION AND LVH: AN ECONOMIC EVALUATION FOR THE NETHERLANDS BASED ON
THE LIFE-STUDY.
Boersma C1, Carides GW2, Burke TA3,
Postma MJ1
1University of Groningen, Groningen, Groningen, Netherlands;
2 Merck Research Labs, Blue Bell, PA, USA; 3 Merck
& Co., Inc, Whitehouse Station, NJ, USA |
|
|
PST3 |
|
CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS
WITH RECENT ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK:
COST-EFFECTIVENESS ANALYSIS IN ITALY.
Rudelli G1, Roze S2, Palmer AJ2, Hakimi
Z3,
Spiesser J3, Carita P3, Gabriel S3
1sanofi-aventis, Milano, Italy; 2 CORE - Center for
Outcomes Research, Binningen, Basel, Switzerland; 3
sanofi-aventis, Bagneux, France |
|
|
PST4 |
|
COST-CONSEQUENCE ANALYSIS FOR THE HANDMASTER IN THE
NETHERLANDS
Nuijten M1, Engelfriet P2
1Erasmus University, Rotterdam, Netherlands; 2
Academic Medical Center, amsterdam, Netherlands |
|
|
PST5 |
|
COST AND OUTCOMES AFTER FIRST STOKE HOSPITAL
ADMISSION: A LONGITUDINAL STUDY USING ADMINISTRATIVE DATABASES
Morsanutto A1, Mantovani L2, Ros B3,
De Portu S2, Spazzapan D3, Tosolini F3
1University of Milan, Milan, Italy; 2 University of
Naples, Naples, Italy; 3 Direzione Regionale della Sanitŕ e
delle Politiche Sociali, Regione Friuli Venezia Giulia, Trieste, Italy |
|
|
PST6 |
|
FACTORS RELATED TO LONGER HOSPITAL STAY AFTER
FIRST-EVER ISCHEMIC STROKE
Tseng MC1, Chang KC2
1National Sun Yat-Sen University, Kaohsiung, Taiwan; 2
Chang Gung Memorial Hospital, Kaohsiung County, Taiwan |
|
|
PST7 |
|
DO PATIENTS WITH ATRIAL FIBRILLATION RECEIVE
APPROPRIATE STROKE PREVENTION THERAPY IN PRACTICE?
Liovas AM1, Folia C2
1AstraZeneca, Mississauga, ON, Canada; 2 Agro
Health Associates, Mississauga, ON, Canada |
|
|
PST8 |
|
WARFARIN PATIENT SEGMENTS: GENERAL PRACTITIONERS
VERSUS SPECIALISTS
Liovas AM
AstraZeneca, Mississauga, ON, Canada |
|
|
PST9 |
|
MANDARIN VERSION OF STROKE IMPACT SCALE: ADAPTATION
AND VALIDATION
Chang KC1, Tseng MC2, Hung JW1,
Lin TK1, Tan TY1, Chen CH1
1Chang Gung Memorial Hospital, Kaohsiung County, Taiwan;
2 National Sun Yat-Sen University, Kaohsiung, Taiwan |
|
|
PST10 |
|
THE METHODOLOGY BEHIND A PROSPECTIVE, OBSERVATIONAL
STUDY OF THE ECONOMIC BURDEN OF ISCHEMIC STROKE
Seung SJ1, Mittmann N2, Sharma M3,
Fisher A4, Cousineau D3, Liovas AM5
1HOPE Research Centre, Sunnybrook & Women's College Health
Sciences Centre, Toronto, ON, Canada; 2 HOPE Research Centre,
Sunnybrook & Women's College Health Sciences Centre, University of
Toronto, Toronto, ON, Canada; 3 The Ottawa Hospital, Ottawa,
ON, Canada; 4 The Ottawa Hospital, University of Ottawa,
Ottawa, ON, Canada; 5 AstraZeneca, Mississauga, ON, Canada |
|
|
PST11 |
|
THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH
CARE. DOES METHOD USED INFLUENCE OUTCOME?
Van Til JA1, Dolan JG2, Stiggelbout AM3,
IJzerman MJ1
1University of Twente / Roessingh Research and Development,
Enschede, Overijssel, Netherlands; 2 Unity Health System,
Rochester, NY, USA; 3 Leiden University Medical Center,
Leiden, Zuid-Holland, Netherlands |
|
|
PST12 |
|
THE USE OF MULTI-CRITERIA DECISION METHODS IN HEALTH
CARE. WHICH METHOD IS MOST SUITABLE FOR HEALTHY AND COGNITIVELY IMPAIRED
POPULATION?
Van Til JA1, Stiggelbout AM2, Dolan JG3,
IJzerman MJ4
1University of Twente, Enschede, Overijssel, Netherlands;
2 Leiden University Medical Center, Leiden, Zuid-Holland,
Netherlands; 3 Unity Health System, Rochester, NY, USA; 4
University of Twente / Roessingh Research and Development, Enschede,
Overijssel, Netherlands |
|
|
PST13 |
|
EFFECTIVENESS OF AN EARLY REHABILITATION STRATEGY
WITH HOME FOLLOW-UP FOR PATIENTS WITH ISCHEMIC VASCULAR CEREBRAL DISEASE
IN MEXICO
Torres-Arreola LDP1, Flores-Hernández S2,
Constantino-Casas P2
1Instituto Mexicano del Seguro Social, Mexico, D.F, Mexico;
2 Instituto Mexicano del Seguro Social, México, D.F, Mexico |
|
|
|
|
.........................TOP |
|
|
|
|
8th Annual European Congress Main Page
|
|
